VCYT vs. CDNA
VCYT (Veracyte, Inc.) and CDNA (CareDx, Inc) are both stocks. Both are in the Healthcare sector — VCYT in Biotechnology, CDNA in Diagnostics & Research. Over the past 10 years, VCYT returned 25.08%/yr vs 25.04%/yr for CDNA. Their 0.43 correlation means their historical movements had little consistent relationship.
Performance
VCYT vs. CDNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, VCYT achieves a 10.02% return, which is significantly lower than CDNA's 132.01% return. Both investments have delivered pretty close results over the past 10 years, with VCYT having a 25.08% annualized return and CDNA not far behind at 25.04%.
VCYT
- 1D
- -22.52%
- 1M
- -18.85%
- 6M
- 21.64%
- YTD
- 10.02%
- 1Y
- 95.94%
- 3Y*
- 19.65%
- 5Y*
- 0.78%
- 10Y*
- 25.08%
- ALL TIME*
- 10.48%
CDNA
- 1D
- 14.72%
- 1M
- 49.74%
- 6M
- 112.70%
- YTD
- 132.01%
- 1Y
- 257.69%
- 3Y*
- 60.92%
- 5Y*
- -12.26%
- 10Y*
- 25.04%
- ALL TIME*
- 13.52%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
CDNA CareDx, Inc | $44.41M | $43.11M | $27.26M |
VCYT Veracyte, Inc. | $76.67M | $68.47M | $67.41M |
VCYT vs. CDNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
VCYT Veracyte, Inc. | 10.02% | 6.31% | 43.95% | 15.93% | -42.40% | -15.82% | 75.29% | 121.94% | 92.65% | -15.63% |
CDNA CareDx, Inc | 132.01% | -12.00% | 78.42% | 5.17% | -74.91% | -37.23% | 235.88% | -14.20% | 242.51% | 171.85% |
Correlation
The correlation between VCYT and CDNA is 0.49, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.49 |
Correlation (3Y) Balances recent behavior with more history. | 0.53 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.62 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.48 |
Correlation (All Time) Calculated using the full available price history since Jul 17, 2014 | 0.43 |
The correlation between VCYT and CDNA shifts across timeframes, from 0.43 (all time) to 0.62 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
VCYT:
$3.70B
CDNA:
$2.26B
VCYT:
$1.41
CDNA:
$2.10
VCYT:
32.79
CDNA:
20.81
VCYT:
0.20
CDNA:
0.03
VCYT:
6.68
CDNA:
5.04
VCYT:
2.73
CDNA:
5.49
VCYT:
$561.90M
CDNA:
$458.09M
VCYT:
$405.67M
CDNA:
$225.02M
VCYT:
$126.58M
CDNA:
$129.64M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VCYT vs. CDNA — Risk / Return Rank
VCYT
CDNA
VCYT vs. CDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Veracyte, Inc. (VCYT) and CareDx, Inc (CDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VCYT | CDNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.08 | ||
| Sortino ratioReturn per unit of downside risk | -2.20 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.54 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | 2.49 | 10.90 | -8.41 |
| Martin ratioReturn relative to average drawdown | 5.48 | 32.58 | -27.10 |
Loading charts...
Drawdowns
VCYT vs. CDNA - Drawdown Comparison
The maximum VCYT drawdown since its inception was -81.19%, smaller than the maximum CDNA drawdown of -94.87%. Use the drawdown chart below to compare losses from any high point for VCYT and CDNA.
Loading charts...
Drawdown Indicators
| VCYT | CDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -81.19% | -94.87% | +13.68% |
Max Drawdown (1Y)Largest decline over 1 year | -39.23% | -23.64% | -15.59% |
Max Drawdown (3Y)Largest decline over 3 years | -50.09% | -65.96% | +15.87% |
Max Drawdown (5Y)Largest decline over 5 years | -71.54% | -94.19% | +22.65% |
Max Drawdown (10Y)Largest decline over 10 years | -81.19% | -94.87% | +13.68% |
Current DrawdownCurrent decline from peak | -43.08% | -54.28% | +11.20% |
Average DrawdownAverage peak-to-trough decline | -48.14% | -53.87% | +5.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.77% | 7.89% | +9.88% |
Volatility
VCYT vs. CDNA - Volatility Comparison
The current volatility for Veracyte, Inc. (VCYT) is 29.33%, while CareDx, Inc (CDNA) has a volatility of 35.19%. This indicates that VCYT experiences smaller price fluctuations and is considered to be less risky than CDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| VCYT | CDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 29.33% | 35.19% | -5.86% |
Volatility (6M)Calculated over the trailing 6-month period | 48.25% | 53.85% | -5.60% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.08% | 72.08% | -7.00% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 64.89% | 79.44% | -14.55% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 62.58% | 79.08% | -16.50% |
Dividends
VCYT vs. CDNA - Dividend Comparison
Neither VCYT nor CDNA has paid dividends to shareholders.
Financials
VCYT vs. CDNA - Financials Comparison
This section allows you to compare key financial metrics between Veracyte, Inc. and CareDx, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
VCYT vs. CDNA - Profitability Comparison
VCYT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Veracyte, Inc. reported a gross profit of 109.13M and revenue of 150.32M. Therefore, the gross margin over that period was 72.6%.
CDNA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, CareDx, Inc reported a gross profit of 0.00 and revenue of 131.95M. Therefore, the gross margin over that period was 0.0%.
VCYT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Veracyte, Inc. reported an operating income of 21.78M and revenue of 150.32M, resulting in an operating margin of 14.5%.
CDNA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, CareDx, Inc reported an operating income of 113.22M and revenue of 131.95M, resulting in an operating margin of 85.8%.
VCYT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Veracyte, Inc. reported a net income of 25.49M and revenue of 150.32M, resulting in a net margin of 17.0%.
CDNA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, CareDx, Inc reported a net income of 110.64M and revenue of 131.95M, resulting in a net margin of 83.9%.
Frequently Asked Questions
VCYT and CDNA have a correlation of 0.49, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CDNA has higher volatility (35.19%) compared to VCYT (29.33%). In terms of maximum drawdown, VCYT dropped -81.19% vs CDNA's -94.87%.
CDNA currently has the higher Sharpe Ratio (3.58 vs 1.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for VCYT and CDNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer